- Home
- SSP vs ENGN Comparison
SSP vs ENGN Comparison
Compare SSP & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSP | ENGN |
|---|---|---|
| Founded | 1878 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Broadcasting | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.2M | 379.3M |
| IPO Year | 1988 | N/A |
Fundamental Metrics
Financial Performance| Metric | SSP | ENGN |
|---|---|---|
| Price | $4.71 | $8.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.50 | ★ $22.71 |
| AVG Volume (30 Days) | ★ 1.3M | 331.3K |
| Earning Date | 11-06-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,318,706,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $2.65 |
| 52 Week High | $4.98 | $11.14 |
Technical Indicators
Market Signals| Indicator | SSP | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 57.23 |
| Support Level | $4.27 | $7.57 |
| Resistance Level | $4.98 | $8.47 |
| Average True Range (ATR) | 0.35 | 0.63 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 75.25 | 69.75 |
Price Performance
Historical ComparisonAbout SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.